Table 1 Overview of included studies
Study, design, year | Malignancy | Research aim | Cohort |
|---|---|---|---|
Guo et al. Comparative study 2019 | CNS B-ALL | CSF-proteome when affected by CNS infiltration of B-ALL | B-ALL (n = 6, CNS positive on “examination”) Healthy controls (n = 6) |
Trueworthy et al. Comparative study (poster presentation) 2006 | CNS B-ALL | CSF-proteome when affected by CNS infiltration of B-ALL | (1) two subgroups of morphologically negative CSF samples on PCR technique of centrifuged cell lysates: First subgroup: MRD negative (n = 3) Second subgroup: MRD positive (n = 3), and (2) morphologically positive CSF patients (n = 2) |
Fei Mo Comparative study 2019 | CNS B-ALL | CSF-proteome before and after ITC + induction therapy of CNS positive B-ALL | B-ALL (n = 6) |
Yu et al. Comparative study 2020 | CNS B-ALL | Proteomic alterations in CSF induced by chemotherapy | B-ALL (n = 9) |
Priola et al. Comparative study 2015 | CNS B-ALL CNS T-ALL | Proteomic alterations in CSF correlated with thromboembolic events and induced by chemotherapy | B-ALL (n = 2) T-ALL (n = 2) |
Reichl et al. Comparative study 2020 | Brain tumor | To quantify CSF-proteome of recurrent medulloblastoma | Recurrent cases of medulloblastoma and prior to treatment (n = 8) Controls (n = 7): age-matched non-neoplastic. Not further elaborated |
Rajagopal et al. Comparative study 2011 | Brain tumor | To investigate putative CSF-proteome biomarkers in medulloblastoma patients | Medulloblastoma (n = 33) Controls (n = 25): age-matched, “leftover samples drawn for other clinical purposes” |
de Bont Comparative study 2006 | Brain tumor | To detect differences in protein expression profiles of CSF from pediatric patients with and without brain tumors | Medulloblastoma (n = 16); high-grade glioma (n = 7); atypical rhabdoid tumor (n = 2); pilocytic astrocytoma (n = 2); plexus carcinoma (n = 2); anaplastic ependymoma (n = 2); germ cell tumor (n = 1) Control (n = 70; lumbar puncture of pediatric patients 1 year after treatment of ALL [n = 47]; infection [n = 6]; hematological disease [n = 4]; autoimmune disease [n = 2]; idiopathic intracranial hypertension [n = 1]; extra-CNS Hodgkin’s [n = 6]; neuroblastoma [n = 4]) |
Spreafico et al. Comparative study 2017 | Brain tumor | To characterize the CSF proteome of patients with CSF tumors and to identify biomarkers predictive of metastatic sprea | Medulloblastoma (n = 18); grade II and III ependymoma (n = 1 and 4); PNET (n = 2); AT/RT (n = 1); high-grade glioma (n = 1) Controls (n = 13, extra-CNS non-Hodgkin’s lymphoma) |
Saratsis et al. Comparative study 2012 | Brain tumor | Exploratory study of CSF proteome in pediatric glioma patients | DIPG (n = 10) GBM (n = 1) Age-matched controls (n = 4, not further elaborated) |
Bruschi et al. Comparative study 2021 | Brain tumor | Putative biomarkers for specific brain tumor subtypes | Pilocytotic astrocytoma (n = 8) Gangliocytoma (n = 3) Medulloblastoma (n = 7), AT/RT (n = 2) PNET (n = 1) Other (n = 8) Controls (n = 17, congenital hydrocephalus) |